| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 10/14/2004 | WO2004000781A3 Nitrooxyderivatives of cyclooxygenase-2 inhibitors |
| 10/14/2004 | WO2003065985A3 Uses of mammalian cytokine; related reagents |
| 10/14/2004 | WO2003031475A8 Antibodies against kdr, their production and uses |
| 10/14/2004 | WO2002030980A8 Use of anti-human integrin alpha d antibodies to treat spinal cord injury |
| 10/14/2004 | US20040205835 Jak kinases and regulation of cytokine signal transduction |
| 10/14/2004 | US20040204599 an end-terminal group, which is isopropyl, sec.-butyl, or tert.-butyl group; a leading group; and a long-chain aliphatic, non-cyclic, saturated or unsaturated, hydrocarbon group that links end-terminal group and leading group; for cancer therapy, prevention, and immune boosting and inflammation functions |
| 10/14/2004 | US20040204588 aryl hydrocarbon; oxidation of 4,5-dihydro-1,3-azoles to fully unsaturated ring; heterocyclic ketones |
| 10/14/2004 | US20040204578 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 10/14/2004 | US20040204568 Comprises nucleotide sequences coding cell adhesion molecules for use in the diagnosis, prevention and treatment of autoimmune and cell proliferative disorders |
| 10/14/2004 | US20040204565 Use of multivalent chimeric peptide-loaded, MHC/IG molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
| 10/14/2004 | US20040204494 Having anticancer, anti-proliferous and anti-inflammatory effects and immunosuppressive and muscle relaxing functions |
| 10/14/2004 | US20040204481 Activation of natural killer cells by adenosine A3 receptor agonists |
| 10/14/2004 | US20040204465 Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide |
| 10/14/2004 | US20040204464 Isoxazoline compounds having MIF antagonist activity |
| 10/14/2004 | US20040204449 New isoquinoline compounds |
| 10/14/2004 | US20040204438 such as N-[4-(4-amino-1H-imidazol[4,5-c]quinolin-1-yl)butyl]-5-(dimethylamino)-naphthalenesulfonamide; for induction of biosynthesis of cytokines; immunomodulators; antineoplastic agents |
| 10/14/2004 | US20040204437 Substituted arylamine derivatives and methods of use |
| 10/14/2004 | US20040204436 Imidazonaphthyridines |
| 10/14/2004 | US20040204425 Sodium channel blockers |
| 10/14/2004 | US20040204418 For prophylaxis and therapy of asthma, chronic obstructive pulmonary disease, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilia, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease |
| 10/14/2004 | US20040204408 Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity |
| 10/14/2004 | US20040204399 Aerosolized decongestants for the treatment of sinusitis |
| 10/14/2004 | US20040204368 Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient |
| 10/14/2004 | US20040204361 Kdel receptor inhibitors |
| 10/14/2004 | US20040204355 alpha 7 receptor is the alpha -bungarotoxin sensitive receptor that influences the release of proinflammatory cytokines from macrophages |
| 10/14/2004 | US20040204345 Using recombinant zinc finger proteins; use in human therapeutic applications such as cancer therapy and altering plant phenotypes, including disease resistance, fruit ripening |
| 10/14/2004 | US20040203118 Polynucleotides and polypeptides of the IFNalpha-14 gene |
| 10/14/2004 | US20040203099 Conjugate of a transport protein and a protein for modulation of notch signalling |
| 10/14/2004 | US20040203098 Compounds and methods for modulating activation of NF-kappaB |
| 10/14/2004 | US20040203097 Kinases and phosphatases |
| 10/14/2004 | US20040203014 Neurotransmisson-associated proteins |
| 10/14/2004 | US20040202676 using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process |
| 10/14/2004 | US20040202671 helminths obtained from preparatory animals raised in a specific human pathogen-free environment used to treat an excessive immune response including an aberrant/enhanced Th1 response, e.g., Crohn's disease and ulcerative colitis |
| 10/14/2004 | US20040202662 Humanised antibodies |
| 10/14/2004 | US20040202660 orally administering an immunoglobulin to modulate serum IgG and/or TNF- Delta levels for treatment of autoimmune disorders, potentiation of vaccination protocols, and improvement of overall health and weight gain in animals, including humans. |
| 10/14/2004 | US20040202657 Humanized anti-CD3 specific antibodies |
| 10/14/2004 | US20040202651 Uses of anti-insulin-like growth factor 1 receptor antibodies |
| 10/14/2004 | US20040202650 Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA-4 specific antibodies |
| 10/14/2004 | US20040202647 T cell line specific for a nitrotyrosine-containing compound; antibody specific for a self-antigen comprising a tyrosine to nitrotyrosine conversion; prevention and treatment of autoimmune diseases, infectious diseases and cancer through the recognition of compounds containing nitrated tyrosine residues |
| 10/14/2004 | US20040202624 Galenical formulation |
| 10/14/2004 | US20040202617 Delivery of opioids through an inhalation route |
| 10/14/2004 | DE10315025A1 Wirkstoffkombination von ω3-fettsäurehaltigen Ölen mit polyphenolhaltigen Pflanzenextrakten und deren Verwendung Combination of active ingredients of ω3-fatty acid-containing oils with polyphenol plant extracts and their use |
| 10/14/2004 | CA2734606A1 Polypeptide comprising cell adhesion motif, t cell epitope and b cell epitope for inducing antibody production |
| 10/14/2004 | CA2523126A1 Thiazoles useful as inhibitors of protein kinases |
| 10/14/2004 | CA2523125A1 Thiazoles useful as inhibitors of protein kinases |
| 10/14/2004 | CA2521050A1 Immunostimulatory nucleic acid oil-in-water formulations and related methods of use |
| 10/14/2004 | CA2521040A1 Active ingredient combinations of plant oils containing .omega.3-fatty acids and plant extracts containing polyphenols and the use thereof |
| 10/14/2004 | CA2520830A1 Method for inducing differentiation and/or proliferating regulatory t cells using anti-cd52 antibodies and pharmaceutical composition therefor |
| 10/14/2004 | CA2520627A1 Composition for preventing or treating allergic disease using black rice extract and its therapeutic use |
| 10/14/2004 | CA2520580A1 Histamine binding compounds for treatment method for disease conditions mediated by neutrophils |
| 10/14/2004 | CA2519958A1 Pharmaceutical composition comprising a macrolide immunomodulator |
| 10/13/2004 | EP1466914A1 Amorphous substance of tricyclic triazolobenzazepine derivative |
| 10/13/2004 | EP1466913A1 Benzoylecgonine, ecgonine and ecgonidine derivatives |
| 10/13/2004 | EP1466622A1 Medicinal agent and method for curing diseases accompanied with vascular dystonia |
| 10/13/2004 | EP1466613A1 Compositions for mucosal and oral administration comprising hCG fragments |
| 10/13/2004 | EP1466608A1 Herbal composition comprising Angelica gigantis, Cnidium officinale and Paeonia japonica |
| 10/13/2004 | EP1466604A1 Isoquinoline derivatives, process for their preparation and use thereof in the treatment of melatoninergic system problems |
| 10/13/2004 | EP1466017A2 Tissue rejection |
| 10/13/2004 | EP1465996A2 Raf/ras binding compounds |
| 10/13/2004 | EP1465924A2 Modulators of notch ic protease activity for use in immunotherapy |
| 10/13/2004 | EP1465920A2 Mammalian simp protein, gene sequence and uses thereof in cancer therapy |
| 10/13/2004 | EP1465891A2 Inhibitors of dipeptidyl peptidase iv |
| 10/13/2004 | EP1465889A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| 10/13/2004 | EP1465863A1 Potassium channel modulators |
| 10/13/2004 | EP1465854A2 Chalcone derivatives and their use to treat diseases |
| 10/13/2004 | EP1465662A1 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound |
| 10/13/2004 | EP1465658A2 Oral vaccination |
| 10/13/2004 | EP1465654A2 Plasmid mediated suplementation for treating chronically ill subjects |
| 10/13/2004 | EP1465649A2 Methods and compositions for derepression of iap-inhibited caspase |
| 10/13/2004 | EP1465631A2 Pyrimidine a2b selective antagonist compounds, their synthesis and use |
| 10/13/2004 | EP1465607A1 Pharmaceutical formulations with modified release |
| 10/13/2004 | EP1465596A1 Polymeric gel system for the controlled delivery of codrugs |
| 10/13/2004 | EP1465577A2 Methods for improving the aesthetic appearance of skin |
| 10/13/2004 | EP1397137A4 Hydantion derivatives as inhibitors of matrix metalloproteinases |
| 10/13/2004 | EP1322309A4 High affinity small molecule c5a receptor modulators |
| 10/13/2004 | EP1280820B1 Anti-inflammatory compounds and uses thereof |
| 10/13/2004 | EP1280797B1 Inhibitors of dipeptidyl peptidase iv |
| 10/13/2004 | EP1207866B1 Delayed-action form of administration containing tramadol saccharinate |
| 10/13/2004 | EP1202628B1 Novel hypoxanthine and thiohypoxanthine compounds |
| 10/13/2004 | EP1169038A4 Cyclic protein tyrosine kinase inhibitors |
| 10/13/2004 | EP1165533B1 Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
| 10/13/2004 | EP1150954B1 Anti-imflammatory indole derivatives |
| 10/13/2004 | EP1131340B1 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis |
| 10/13/2004 | EP1097934B1 Lk6-a derivatives |
| 10/13/2004 | EP1097142B1 Phthalazine derivatives phosphodiesterase 4 inhibitors |
| 10/13/2004 | EP1086086B1 Imidazolyl derivatives and their use as somatostatin receptor ligands |
| 10/13/2004 | EP0873136B1 High fluorescence specific immune enhancing factor and methods of use for same |
| 10/13/2004 | EP0840616B1 Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies, as therapeutic agents for the treatment of immunological diseases |
| 10/13/2004 | EP0839155B1 CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES |
| 10/13/2004 | EP0817847B1 Il-17 receptor |
| 10/13/2004 | EP0812588B1 Pharmaceutical external preparations for topical administration comprising 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for the treatment of diseases induced from immune disorder |
| 10/13/2004 | EP0802912B1 Piperidine derivatives having tachykinin antagonist activity |
| 10/13/2004 | EP0736036B1 Kininogen inhibitors |
| 10/13/2004 | CN1537111A Urea substituted imidazoquinolines |
| 10/13/2004 | CN1537100A Substituted 2-pyrrole cyclohexan-1,4-diamine derivatives |
| 10/13/2004 | CN1537025A 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1.1-dioxo-1 lambda b-thiomorpholin-4-yl)-4-(methyl or 4-fluoro-2-methyl substituted)phenyl-pyridin-3-yl]-N-methyl-isobutyramide |
| 10/13/2004 | CN1537019A Medical combination of aldosterone receptor antagonist and HMG CoA reductase inhibitor |
| 10/13/2004 | CN1537017A Remedie for inflammatory bowel diseases |
| 10/13/2004 | CN1537015A Stable liquid formulations of antibodies |
| 10/13/2004 | CN1537009A Method for treating or preventing functional vitamin B12 dificiency in individual and to medical compositions for use in said method |